The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.

Terns Pharmaceuticals (TERN) is back in focus after presenting encouraging safety and efficacy data for its TERN-701 chronic ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...